Hexarelin vs PT-141
Head-to-head comparison of Hexarelin (Growth Hormone Releasing Hexapeptide) and PT-141 (Bremelanotide (Melanocortin Receptor Agonist)) — benefits, dosing, side effects, research data, and where to buy.
| Property | Hexarelin | PT-141 |
|---|---|---|
| Category | Performance | Performance |
| Full Name | Growth Hormone Releasing Hexapeptide | Bremelanotide (Melanocortin Receptor Agonist) |
| Molecular Weight | 887.04 Da | 1,025.2 Da |
| Half-Life | ~70 minutes | ~2.7 hours |
| Amino Acids | 6 | 7 |
| Typical Dose | 100-200 mcg | 1.75 mg |
| Route | SC / IV | SC |
| Purity | — | — |
| Studies Count | 198 | 178 |
| Research Status | Clinical Trials | FDA Approved |
Hexarelin Benefits
- ✓Strongest GH pulse among GHRPs
- ✓Cardioprotective effects
- ✓Muscle mass and strength gains
- ✓Fat loss through improved body composition
- ✓Enhanced recovery from training
PT-141 Benefits
- ✓Enhances sexual desire and arousal
- ✓Works through CNS (not vascular)
- ✓FDA-approved for HSDD
- ✓Effective for both men and women
- ✓Does not require sexual stimulation to work
Hexarelin Dosing
Standard: 100-200 mcg SC 2-3 times daily|Pre-workout: 100 mcg 30 min before training|Pre-bed: 100 mcg for overnight GH pulse|Cycle: 8-12 weeks then 4 week break (desensitization)
PT-141 Dosing
Standard: 1.75 mg SC, 45 min before activity|Max frequency: Once every 24 hours|Max: 8 doses per month|Men (off-label): 1-2 mg SC as needed
Hexarelin Side Effects
- ⚠Common: Increased appetite, water retention, tingling
- ⚠Moderate: Cortisol and prolactin elevation (dose-dependent)
- ⚠Notable: Desensitization occurs after 4-16 weeks of continuous use
- ⚠Rare: Numbness in extremities
PT-141 Side Effects
- ⚠Common: Nausea (40%), flushing, headache, injection site reactions
- ⚠Moderate: Elevated blood pressure (transient), fatigue
- ⚠Serious: Focal hyperpigmentation with repeated use
- ⚠Contraindications: Uncontrolled hypertension, cardiovascular disease
Research Overview
Hexarelin
Hexarelin has extensive pre-clinical and clinical evidence. Multiple human studies confirm potent GH release. Unique cardioprotective properties are well-documented. Note that receptor desensitization limits long-term continuous use.
PT-141
PT-141 has robust clinical evidence including multiple Phase III trials. FDA-approved in 2019. Unique mechanism of action through melanocortin-4 receptors in the brain. Well-characterized safety and efficacy profile.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.